Ermira Pazolli

This inventor holds 8 USPTO granted patents and 5 published patent applications, plus 2 CIPO patents and 4 EPO patents. Top assignee: Eisai R&d Management Co., Ltd.. Active years: 2016-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Ermira Pazolli. Retrieved from https://idiyas.com/inventor/ermira-pazolli

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 8 (Patent Applications = 5)

% Patents Active = 100.0

CIPO Patents = 2 (Patent Applications = 3)

EPO Patents = 4 (Patent Applications = 6)

Average Co-Inventor Count = 13.8

ph-index = 1

Forward Citations = 3(Granted Patents)

Company Filing History:

8 out of 530

Eisai R&d Management Co., Ltd.

patents

Years Active: 2016-2026

Loading Chart...

8 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12514926 - SPLICING MODULATOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE (2026-01-06),

2. 12172986 - Splicing modulator antibody-drug conjugates and methods of use (2024-12-24),

3. 12043670 - Anti-BCMA antibody-drug conjugates and methods of use (2024-07-23),

4. 11998544 - Methods of using splicing modulators (2024-06-04),

5. 11945807 - Splicing modulator antibody-drug conjugates and methods of use (2024-04-02),

6. 11352348 - Splicing modulator antibody-drug conjugates and methods of use (2022-06-07),

7. 10745387 - Crystalline form of (2S,3S,6S,7R,10R,E)-7,10-dihydroxy-3,7-dimethyl-12-oxo-2-((R,2E,4E)-6-(piridin-2-yl)hepta-2,4-dien-2-yl)oxacyclododec-4-en-6-yl-4-methylpiperazine-1-carboxylate and methods of use thereof (2020-08-18),

8. 9481669 - Pladienolide pyridine compounds and methods of use (2016-11-01),

Certainly! Here is an article about inventor Ermira Pazolli:

Title: Unveiling the Innovations of Ermira Pazolli in Biomedical Research

Introduction:

Ermira Pazolli, a distinguished inventor based in Wayland, MA (US), has made significant contributions to the field of biomedical research. With a keen focus on developing novel therapies for neoplastic disorders, Pazolli has garnered recognition for his innovative approach to drug development.

Latest Patents:

Pazolli's latest patents revolve around splicing modulator antibody-drug conjugates and methods of use. These groundbreaking inventions involve linker-drug compounds and antibody-drug conjugates that specifically target human oncology markers. The incorporation of splicing modulator drug moieties, particularly pladienolide and its derivatives, sets Pazolli's work apart in the realm of cancer therapeutics.

Career Highlights:

Currently affiliated with Eisai R&D Management Co., Ltd., Pazolli continues to drive forward advancements in the pharmaceutical industry. With a total of 4 patents to his name, he has demonstrated a profound commitment to pushing the boundaries of medical science.

Collaborations:

In his pursuits, Pazolli has collaborated closely with esteemed colleagues such as Xiang Liu and Sudeep Prajapati. Together, they have synergized their expertise to further refine the mechanisms of action behind the splicing modulator antibody-drug conjugates.

Conclusion:

In conclusion, Ermira Pazolli stands as a trailblazer in the realm of biomedical innovation, with a remarkable track record of patents that hold great promise in the treatment of neoplastic disorders. His collaborations and career achievements underscore his dedication to advancing the frontiers of medical research for the betterment of society.

Profile summary based on public USPTO records.